Pharmacoeconomics

Article	Citations
The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)	310
A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020)	196
Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018	105
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment	95
International Valuation Protocol for the EQ-5D-Y-3L	85
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis	61
Calculating and Interpreting ICERs and Net Benefit	58
What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study	53
Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States	49
Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach	47
The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers	45
EQ-5D-Y Value Set for Slovenia	44
Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment	41
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations	37
Producing Standardized Country-Level Immunization Delivery Unit Cost Estimates	32
Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines	31
Why it’s Time to Abandon the ICER	30
Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers	30
Economic Evaluation of Digital Health Interventions: Methodological Issues and Recommendations for Practice	28
Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study	28
Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review	27
Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness	27
Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures	27
Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review	26
Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension	26

Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine	24
Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies	23
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel	23
Integrative Review of Managed Entry Agreements: Chances and Limitations	23
Economic Costs of Myasthenia Gravis: A Systematic Review	22
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China	21
The Application and Implications of Novel Deterministic Sensitivity Analysis Methods	21
Productivity-Adjusted Life-Years: A New Metric for Quantifying Disease Burden	21
Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis	20
Health State Utilities of Patients with Heart Failure: A Systematic Literature Review	20
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective	20
Taking the Analysis of Trial-Based Economic Evaluations to the Next Level: The Importance of Accounting for Clustering	19
Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups	19
Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States	19
Overlap of Depressive Symptoms with Health-Related Quality-of-Life Measures	19
Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer	17
Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model	17
EQ-5D-Y Value Set for Germany	16
Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria	16
The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia	16
The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review	16
Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates	16
Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden	16
Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Out	16
Best–Worst Scaling and the Prioritization of Objects in Health: A Systematic Review	15
Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review	15
Modifying NICE’s Approach to Equity Weighting	15
What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma	15
Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US	15
Value Set for the EQ-5D-Y-3L in Hungary	15
Are We Agreed? Self- Versus Proxy-Reporting of Paediatric Health-Related Quality of Life (HRQoL) Using Generic Preference-Based Measures: A Systematic Review and Meta-Analysis	14
A Comparison of PROPr and EQ-5D-5L Value Sets	14
Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol	14
Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic	14
Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer	14
The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA	14
Valuing the AD-5D Dementia Utility Instrument: An Estimation of a General Population Tariff	13
Cost of Nine Pediatric Infectious Illnesses in Low- and Middle-Income Countries: A Systematic Review of Cost-of-Illness Studies	13
Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US	13
Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia	12
A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine	12
Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review	12
Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations	11
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US	11
Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement Framework	11
Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study	11
Using a Modified Delphi Approach to Gain Consensus on Relevant Comparators in a Cost-Effectiveness Model: Application to Prostate Cancer Screening	11
Estimating an EQ-5D-Y-3L Value Set for China	11
Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China	11
Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision	11

A Value Set for the EQ-5D-Y-3L in the Netherlands	11
The Costs of Dementia in Europe: An Updated Review and Meta-analysis	11
External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions	11
Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment	11
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States	11
The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe	11
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)	10
Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness	10
Economic Implications of Endometriosis: A Review	10
Do Costs in the Education Sector Matter? A Systematic Literature Review of the Economic Impact of Psychosocial Problems on the Education Sector	10
The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder	10
Health Economists on Involving Patients in Modeling: Potential Benefits, Harms, and Variables of Interest	10
Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review	10
Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve	10
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer	10
The EQ-5D-5L Valuation Study in Egypt	10
Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis	10
The Challenges of Measuring Informal Care Time: A Review of the Literature	9
Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability	9
The Excess Costs of Depression and the Influence of Sociodemographic and Socioeconomic Factors: Results from the German Health Interview and Examination Survey for Adults (DEGS)	9
Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management	9
Valuing the Quality-of-Life Aged Care Consumers (QOL-ACC) Instrument for Quality Assessment and Economic Evaluation	9
A General Public Study on Preferences and Welfare Impacts of Antimicrobial Resistance in the United Kingdom	8
Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA	8
Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review	8
A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets	8
Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations	8
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden	8
Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal	8
A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population	8
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland	8
Deprescribing Interventions among Community-Dwelling Older Adults: A Systematic Review of Economic Evaluations	8
How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents	8
Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis	8
Postnatal Major Depressive Disorder in Australia: Inequalities and Costs of Healthcare to Individuals, Governments and Insurers	8
Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox–Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	7
Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome	7
Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals	7
Future of Data Analytics in the Era of the General Data Protection Regulation in Europe	7
Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups	7
Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges	7
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)	7
Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers	7
Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments	7
Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic	7
Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review	7
Cost-Effectiveness Analysis of Patiromer in Combination with Renin–Angiotensin–Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden	7
Collaborating with Patient Partners to Model Clinical Care Pathways in Major Depressive Disorder: The Benefits of Mixing Evidence and Lived Experience	7
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review	7
RETRACTED ARTICLE: The EQ-5D-5L Valuation Study in Egypt	7
Real-World Treatment Costs and Care Utilization in Patients with Major Depressive Disorder With and Without Psychiatric Comorbidities in Specialist Mental Healthcare	7
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA	6
Conceptualising ‘Benefits Beyond Health’ in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis	6
Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries	6
EQ-5D-Y Population Norms for Japanese Children and Adolescents	6
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK	6
In a Child’s Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives	6
Preference Elicitation Techniques Used in Valuing Children’s Health-Related Quality-of-Life: A Systematic Review	6
The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions	6
Health Economic Evaluation Alongside Stepped Wedge Trials: A Methodological Systematic Review	6
Living Health Technology Assessment: Issues, Challenges and Opportunities	6
Production Losses due to Absenteeism and Presenteeism: The Influence of Compensation Mechanisms and Multiplier Effects	6
Economic Impact of Insufficient and Disturbed Sleep in the Workplace	6
Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review	6
Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study	6
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada	6
Keeping Pace with Pharmaceutical Innovation: The Importance of the NICE Methods Review	6
Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches	6
Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review	6
Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review	6
Is an Orphan Drug’s Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?	6
Exploring the Issues of Valuing Child and Adolescent Health States Using a Mixed Sample of Adolescents and Adults	6
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial	6
Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis	6
Examining Approaches to Estimate the Prevalence of Catastrophic Costs Due to Tuberculosis from Small-Scale Studies in South Africa	6
The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature	6
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting	6
Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods	6
Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a U	5
Lack of Cost-Effectiveness of Preoperative Erythropoiesis-Stimulating Agents and/or Iron Therapy in Anaemic, Elective Surgery Patients: A Systematic Review and Updated Analysis	5

Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study	5
Calibrating Natural History of Cancer Models in the Presence of Data Incompatibility: Problems and Solutions	5
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review	5
Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles	5
Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values	5
In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era	5
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England	5
Cost-of-Illness Progression Before and After Diagnosis of Multiple Sclerosis: A Nationwide Register-Based Cohort Study in Sweden of People Newly Diagnosed with Multiple Sclerosis and a Population-Base	5
Investigating the Association Between Self-Reported Comorbid Anxiety and Depression and Health Service Use in Cancer Survivors	5
Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review	5
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based	5
Does Cost-Effectiveness Analysis Really Need to Abandon the Incremental Cost-Effectiveness Ratio to Embrace Net Benefit?	5
An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia	5
Assessments of the Value of New Interventions Should Include Health Equity Impact	5
Assessing Technologies for COVID-19: What are the Challenges for Health Technology Assessment Agencies? Findings From a Survey and Roundtable Workshop	5
Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development	5
Replication of Published Health Economic Obesity Models: Assessment of Facilitators, Hurdles and Reproduction Success	5
Toward Modified Impact Inventory Tables to Facilitate Patient-Centered Value Assessment	5
Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies	5
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer	5
Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review	5
EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions	4
The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis	4
Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment	4
What Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK	4
Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis	4
Four Aspects Affecting Health Economic Decision Models and Their Validation	4
Health State Utility Values in Juvenile Idiopathic Arthritis: What is the Evidence?	4
State of the ART? Two New Tools for Risk Communication in Health Technology Assessments	4
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2− Advanced Breast Cancer: A Canadian Healthcare Perspective	4
Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses	4
The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS	4
The Societal Cost of Schizophrenia: An Updated Systematic Review of Cost-of-Illness Studies	4
Macrovascular Risk Equations Based on the CANVAS Program	4
Patient and Public Involvement in Health Economics Modelling Raises the Need for Normative Guidance	4
Correction to: Calculating and Interpreting ICERs and Net Benefit	4
Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	4
Utility Decrements Associated with Adult Overweight and Obesity in Australia: A Systematic Review and Meta-Analysis	4
Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?	4
Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions	4
Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia	4
Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease	4
Is EQ-5D-5L Better Than EQ-5D-3L Over Time? A Head-to-Head Comparison of Responsiveness of Descriptive Systems and Value Sets from Nine Countries	4
Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature	4
Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service	4
Psychometric Properties of Generic Preference-Weighted Measures for Children and Adolescents: A Systematic Review	4
Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency	4
An EQ-5D-Y-3L Value Set for Belgium	4
Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom	4
The Relative Importance of Education and Criminal Justice Costs and Benefits in Economic Evaluations: A Best–Worst Scaling Experiment	3
Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review	3
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer	3
Associating Health-Related Quality-of-Life Score with Time Uses to Inform Productivity Measures in Cost-Effectiveness Analysis	3
Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review	3
Developing an Online Infrastructure to Enhance Model Accessibility and Validation: The Peer Models Network	3
The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer	3
Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated	3
A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome	3
Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation	3
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition	3
Infectious Disease Modelling of HIV Prevention Interventions: A Systematic Review and Narrative Synthesis of Compartmental Models	3
The SF-6Dv2: How Does the New Classification System Impact the Distribution of Responses Compared with the Original SF-6D?	3
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the Unit	3
Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations	3
Correction to: Perspective and Costing in Cost‑Effectiveness Analysis, 1974–2018	3
The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice	3
Sustainability of Publicly Funded Health Care Systems: What Does Behavioural Economics Offer?	3
Adherence to Discounting Guidelines: Evidence from Over 2000 Published Cost-Effectiveness Analyses	3
Findings from a Roundtable Discussion with US Stakeholders on Valuation of the EQ-5D-Y-3L	3
Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome”	3
EQ-5D-5L Value Set for Slovenia	3
Valuing SF-6Dv2 in Australia Using an International Protocol	3
Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations	3
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial	3
Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	3
Projecting the Health and Economic Burden of Cardiovascular Disease Among People with Type 2 Diabetes, 2022–2031	3
Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment	3
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrin	3
A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cos	3
An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year	3
Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	3
Modelling the Cost-Effectiveness of Diagnostic Tests	3
Evaluating New Zealanders’ Values for Drug Coverage Decision Making: Trade-Offs between Treatments for Rare and Common Conditions	3
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry	3
Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia	3
Lifetime Costs for Treated Follicular Lymphoma Patients in the US	3
Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery	3